A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women.
about
Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complicationsPhospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic interventionCollaborative meta-analysis of individual participant data from observational studies of Lp-PLA2 and cardiovascular diseases.Lipoprotein-associated phospholipase A2 as a novel risk marker for cardiovascular disease: a systematic review of the literatureImpact of 8-week linoleic acid intake in soy oil on Lp-PLA2 activity in healthy adults.Lp-PLA2 Inhibition-The Atherosclerosis Panacea?Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study.Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria.Association of lipoprotein-associated phospholipase A2 with coronary artery disease in African-Americans and CaucasiansLp-PLA2 Inhibitors for the Reduction of Cardiovascular EventsClinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study.Lipoprotein-associated phospholipase A2 activity predicts cardiovascular events in high risk coronary artery disease patients.Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis.Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target.Lipoprotein-associated phospholipase A2 and carotid intima-media thickness in individuals classified as low-risk according to Framingham.Lipoprotein-associated phospholipase A2: a target directed at the atherosclerotic plaque.Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk.Inflammatory bio-markers and cardiovascular risk prediction.Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study.C-reactive protein: a surrogate risk marker or mediator of atherothrombosis?Association of Lp-PLA2 Mass and Aysmptomatic Intracranial and Extracranial Arterial Stenosis in Hypertension Patients.Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and AtherosclerosisLipoprotein-associated phospholipase A2 and risk of incident cardiovascular disease in a multi-ethnic cohort: The multi ethnic study of atherosclerosis.Lipoprotein-associated phospholipase A2, vascular inflammation and cardiovascular risk predictionAssessing inflammatory status in cardiovascular disease.Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients.PLAC test for identification of individuals at increased risk for coronary heart disease.Modulation of oxidative stress, inflammation, and atherosclerosis by lipoprotein-associated phospholipase A2Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target.Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke.Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults.Lipoprotein-Associated Phospholipase A2 and Incident Peripheral Arterial Disease in Older Adults: The Cardiovascular Health Study.Clinical utility of lipoprotein-associated phospholipase A₂ for cardiovascular disease prediction in a multiethnic cohort of women.Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas Heart Study.Association of lipoprotein-associated phospholipase A2 with coronary calcification among American and Japanese menThe association between lipoprotein-associated phospholipase A2 and cardiovascular disease and total mortality in vascular medicine patients.Predicting the risk of cardiovascular disease: where does lipoprotein-associated phospholipase A(2) fit in?Lipoprotein-associated phospholipase A(2) : review of its role as a marker and a potential participant in coronary endothelial dysfunction.Relationship of lipoprotein-associated phospholipase A2 and oxidized low density lipoprotein in carotid atherosclerosis.Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study.
P2860
Q26777871-970BD376-12BD-4713-881E-35CB3971AB24Q26997377-6528E531-B78B-4654-BE0B-E91DBD63B1EDQ31100823-58479BAC-7E86-421D-8D1B-072857FBE202Q33536648-1FA0484D-22F7-45D0-834B-AEF07F04CB43Q33651282-BD6E8DA0-09FD-4ED9-8222-42B4DC188212Q33664272-7553DD8B-E147-4665-B2F7-587838F6B61DQ33755952-4F45077E-90C7-4843-8550-E8CE8C2944C6Q33805731-CE04BC05-D283-490C-BC72-875C3C044427Q33849524-6DA24B33-84CD-442B-8F3D-40F9732D4B1CQ33936097-B6A1F519-2FB3-4A85-BB56-CD0531E36762Q33944562-C6B71EC6-AA4A-4574-AD48-B4EE00A2260AQ34464823-E7BB9229-0091-4ACA-B2E1-86073D7F9D37Q34541071-84BDB219-E421-4636-85B0-FB9389238881Q34692452-78DDC052-F58D-40ED-8458-0A4D71D16A4AQ34779570-4244F700-B962-456C-A899-8A848FCFD357Q34837405-9E0AF0CA-84AA-47AD-9C4B-0CF1DF8FC3C9Q34890672-28389367-8CF8-4F78-BEC1-3C00E670A546Q34941391-CF478378-4F18-4B61-B821-FB59BA884E06Q34987055-CC651317-4D7F-4B7E-9413-68B09CDC3FB4Q35558793-3ED771D8-93D9-43FA-96DB-A3FBB6B2D498Q35670588-A81AB87D-F10C-4112-B8BC-BEC30D2DB665Q35764402-1BA90AA3-5EEC-4E31-BF18-A138A46D9F95Q35856590-8BF81913-32E2-4D46-871C-25B45B65C241Q36013005-848CD235-3E7D-4F92-AA72-4D8C607961FDQ36014020-326D35BD-F8EC-483E-A888-3D99B9D7C229Q36024430-1888164D-923E-4B35-ABED-B4565842DC03Q36050527-87D6B0CE-03B2-4951-B13F-1A0E466F9336Q36145180-201D5EED-9D15-47E8-80AA-14C5C6F0FF21Q36187055-6795F29C-60A8-4E63-AA92-3F6F9D1391FBQ36269180-552575AC-6E22-4FAD-A185-C308900BCB59Q36540286-3D65522A-9C5F-4086-A93F-5019C13291EAQ36730558-EEF1B632-1208-4A8F-BFF0-3E3C8CB07903Q36752159-BD6DE661-3E9A-4D30-835B-811D22D0C4BBQ36808689-46782227-06C1-4B76-8686-914BBAE9D680Q36861883-F48B6937-6C7E-47B7-A138-2023F6A31F35Q36903325-B821749A-5D81-4967-BC86-7480CA5B6E22Q36913018-9C192C8E-91E2-486C-8A9C-90914CEAD0E2Q36913022-F34E375B-5FA1-48F1-B056-6514A7C4C601Q37299885-B7CC3096-93CD-4734-B100-2DBA8AF3C4A4Q37374474-93AFFDD2-3120-4D48-8BF8-B69B1E1F260F
P2860
A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
A prospective evaluation of li ...... ardiovascular events in women.
@en
type
label
A prospective evaluation of li ...... ardiovascular events in women.
@en
prefLabel
A prospective evaluation of li ...... ardiovascular events in women.
@en
P2093
P1476
A prospective evaluation of li ...... ardiovascular events in women.
@en
P2093
P304
P356
10.1016/S0735-1097(01)01554-6
P407
P577
2001-11-01T00:00:00Z